Articles related to Hematology/Oncology

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

UnitedHealthcare’s decision to bundle G2211 into E/M payments for commercial plans signifies a shift in reimbursement strategies that oncologists need to address promptly.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.

Nearly 70% of 340B contract pharmacies are now associated with pharmacy benefit managers, potentially shifting the program’s focus away from its original intent of supporting safety-net providers.

The loss of two oncology residents in a plane crash has left a significant void in cancer care at a major oncology center in Paraná, Brazil, highlighting the critical role of specialized medical professionals in smaller communities.